Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06029426 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder
A Phase 3 study, sponsored by Neumora Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 383
- Enrollment target
NCT06029426: Completed Phase 3 study, sponsored by Neumora Therapeutics.
NCT06029426 is a Phase 3 study that has completed, run by Neumora Therapeutics. The registered enrollment target is 383 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (50% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06029426, a Phase 3 study, has completed, sponsored by Neumora Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 383 participants
- Enrollment target
Study Summary
This is a randomized, double blind, placebo controlled, multi-center study to evaluate the effects of NMRA-335140 (formerly BTRX 335140) on symptoms of depression in participants with Major Depressive Disorder (MDD). The study design consists of a Screening Period (up to 28 days), and a 6-week Treatment Period (during which participants will receive either NMRA-335140 or placebo). At the completion of the 6-week Treatment Period, participants who complete the study, provide informed consent, and meet the eligibility criteria may enter an extension study (NMRA-335140 501).
Primary Outcome
The MADRS is a 10-item, clinician-rated scale that evaluates the participant's depressive symptomatology during the past week. Participants are rated on items assessing feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty in concentration, and lack of interest. Each item will be scored on a 7-point scale with a score of 0 reflecting no symptoms and a score of 6 reflecting symptoms of maximum severity. Thus, scores in the MADRS range from 0
Interventions
- DRUG Placebo
- DRUG NMRA-335140
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 383 participants |
| Start Date | 2023-09-20 |
| Est. Completion | 2025-01-15 |
| Phase | Phase 3 |
What the finished NCT06029426 record still lists
NCT06029426 is an interventional study that assigns participants to a tested intervention. The registered 383 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (50% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06029426 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06029426 about?
NCT06029426 is a clinical study titled "Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder". This is a randomized, double blind, placebo controlled, multi-center study to evaluate the effects of NMRA-335140 (formerly BTRX 335140) on symptoms of depression in participants with Major Depressive Disorder (MDD). The study design consists of a Screening Period (up to 28 days), and a 6-week Treat...
What is the current status of trial NCT06029426?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 383 participants. The study started on 2023-09-20. Estimated completion is 2025-01-15.
What interventions are being tested in trial NCT06029426?
The interventions under investigation include: Placebo (DRUG), NMRA-335140 (DRUG).
Who is sponsoring clinical trial NCT06029426?
This trial is sponsored by Neumora Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06029426's enrollment target sits among peer trials
383 976th of 2000 higher than 1,023 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06056830 · 383 participants · Phase 3
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
- NCT06277661 · 384 participants · NA
The Mom and Infant Outcomes (MOMI) Study
- NCT06372964 · 384 participants · Phase 3
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
- NCT06501040 · 384 participants · NA
Increasing Knowledge and Interest in Cancer Clinical Trials
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI